CDNA - CareDx, Inc

CareDx, Inc

8000 Marina Boulevard
Brisbane
South San Francisco, CA 94005
United States
415 287 2300
https://www.caredx.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 727

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Reginald Seeto M.D., MBBS	Pres, CEO & Director	954.71k	N/A	1972
Mr. Abhishek Jain	CFO & Principal Accounting Officer	425.58k	N/A	1977
Mr. Abraham Ronai Esq.	Chief Admin. & Legal Officer and Sec.	566.49k	N/A	1974
Dr. Peter Maag Ph.D.	Exec. Director	43.23k	N/A	1967
Ms. Sasha King M.B.A.	Exec. Officer	343.34k	325.59k	1986
Mr. Alexander L. Johnson	Pres of Patient and Testing Services	547.43k	N/A	1975
Ms. Marica Grskovic Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Mr. Ian Cooney	VP of Investor Relations	N/A	N/A	N/A
Dr. Mickey Y. Kim M.D.	Sr. VP of Corp. Devel. & Head of Global Product	N/A	N/A	N/A
Mr. Jarrod Borkat	Sr. VP and Head of Marketing & Portfolio Operations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

CareDx, Inc’s ISS Governance QualityScore as of May 30, 2023 is 7. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.